和黄医药押注抗癌药。图片来源:图虫创意3月19日晚间,李嘉诚家族旗下创新药企和黄医药(00013.HK;HCM.US)发布2024年全年业绩。财报显示,和黄医药全年综合收入总额为6.302亿美元,同比减少约24%;应占净收益3772.9万美元,同比减少约62%,但截至2024年12月31日,和黄医药现金余额为8.361亿美元(折合人民币约为60.50亿元),公司将继续在财务上自给自足,同时支持投资...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.